Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-067723
Filing Date
2024-08-12
Accepted
2024-08-12 16:45:38
Documents
32
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0211026-10q_raphael.htm   iXBRL 10-Q 260586
2 CERTIFICATION ea021102601ex31-1_raphael.htm EX-31.1 11023
3 CERTIFICATION ea021102601ex31-2_raphael.htm EX-31.2 10943
4 CERTIFICATION ea021102601ex32-1_raphael.htm EX-32.1 3210
5 CERTIFICATION ea021102601ex32-2_raphael.htm EX-32.2 3361
  Complete submission text file 0001213900-24-067723.txt   1404053

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE raph-20240630.xsd EX-101.SCH 18135
7 XBRL CALCULATION FILE raph-20240630_cal.xml EX-101.CAL 12563
8 XBRL DEFINITION FILE raph-20240630_def.xml EX-101.DEF 64289
9 XBRL LABEL FILE raph-20240630_lab.xml EX-101.LAB 149795
10 XBRL PRESENTATION FILE raph-20240630_pre.xml EX-101.PRE 69423
35 EXTRACTED XBRL INSTANCE DOCUMENT ea0211026-10q_raphael_htm.xml XML 75783
Mailing Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108
Business Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108 702-442-1166
Raphael Pharmaceutical Inc. (Filer) CIK: 0001415397 (see all company filings)

EIN.: 260204284 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-53002 | Film No.: 241197528
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)